Pharmaeconomics in asthma
- PMID: 26920490
- DOI: 10.1016/j.arbres.2016.02.001
Pharmaeconomics in asthma
Comment on
-
Comparison of Costs and Clinical Outcomes Between Hospital and Outpatient Administration of Omalizumab in Patients With Severe Uncontrolled Asthma.Arch Bronconeumol. 2016 Apr;52(4):211-6. doi: 10.1016/j.arbres.2015.10.004. Epub 2015 Dec 3. Arch Bronconeumol. 2016. PMID: 26651624 English, Spanish.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
